🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

It's The Lancet Oncology day for Rad Onc GU! Our consensus on SBRT for Oligomets RCC is finally out! Thanks to all the participants! 🔥🔥🔥🌟🌟🌟 Delphi consensus on stereotactic ablative radiotherapy for oligometast... sciencedirect.com/science/articl…

Good comment

💯

Funny!

🔥⚡️🚀 Proud to be part of the PEACE V–STORM trial paper in The Lancet Oncology! MDT vs elective nodal RT in oligorecurrent nodal prostate cancer. Thanks to Petra Ost, Thomas Zilli & team for the great work and for including me! Free access: authors.elsevier.com/c/1l2Mc5EIIgTR…

Tyler Seibert MD PhD Tony Felefly Neil Desai Dr. Andrew Loblaw Daniel E Spratt Robert Dess SOUMYAJIT ROY Amar Kishan I wouldn’t typically treat UIR with brachy mono. Brachy data is excellent for FIR. Much more parsing of this data set needed before drawing any conclusion Tyler Seibert MD PhD. Your handle IS SBRT though so 😉

A game changer! Now we should be asking about other nodal sites too (like para-aortics) and maybe a little more efficient dose (like 25/5 to ENI)? Management of oligometastatic HSPC is a huge area of patient need that we can lead in. Let’s go! 🚀

Congrats Giulia Marvaso‼️ Can’t wait to read 👓

Plus I love the cover - releasing the Canadian Loons

It was a privilege to be a part of this guideline. Great that we have clear guidance to improve patient outcomes.

I often have to pause and remind myself… 10 year old data reflects techniques and our understanding of the time. We didn’t know the difference b/w FIR & UIR. It was Zumsteg and Daniel E Spratt from 2013. But now I would I would treat UIR with ENI, ADT + brachy (or PR24)

PCS XI, HOPE and SHARP are all RCTs examining this question. PCS XI is phase 3, the other two phase 2. But together we’ll have good data on efficacy in 3-5y. We do have prospective data > 10y FU (SATURN, 5STAR, SHARP) but patient #s were small (about 30 pts in each cohort)

A rockstar radonc Dr. Andrew Loblaw once told me it’s always comforting when you find a study that confirms your biases. This gem I’ve been waiting for for a while now… thelancet.com/journals/lanon…

Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update. Read more. brnw.ch/21wSvsv

The latest guidance from ASCO on management on mCRPC. Proud to contributing to this guideline since 2004. The best way to improve patient outcomes is from following high quality evidence. Check it out! 👇🏻

It’s one thing to believe… and another to believe and be correct (I’m looking at you #FlatEarthers). STORM/PEACE-V further validates role of RT in mHSPC.

OMG 😱 What an incredible legacy (and loss). But the future is bright because he supported the next generation of leaders.

We were fortunate to have a strong collaborative team UCLA Jonsson Comprehensive Cancer Center including UCLA Urology, as well as a comparator cohort of patients receiving conventionally fractionated IMRT at UChicago Medicine Stan Liauw and Connor Lynch

That’s devastating to hear Ale. I’m glad the family is safe physically but I’m sure no one is resting well these days.

But now it’s different. MRI or high frequency US identifies 5% ⬆️ clinically significant ds (absolute %; 20% relative) and 10% ⬇️ grade 1 ds (50% relative). And over 80% of men with GG1 go on active surveillance (at least in Ontario). Lastly #PLCO was deeply flawed